Thus, any comparison must be based on existing data from liraglutide's phase 3 trials and retatrutide's phase 2 trials: According to a 2016 systematic review of 43 randomized trials, liraglutide has shown significant benefits for T2D, with doses ranging from 1.2-1.8mg/daily leading to HbA1c decreases between -0.9% and -2.2% over six months
Back Holst, JJ (26 April 2019) 'From the Incretin Concept and the discovery of GLP-1 to today's diabetes therapy', Frontiers in Endocrinology , 10
Enrico Barichello and Courtney Nicholas Sutton describe the innovative combination of SHLs Molly autoinjector with Stevanatos Alba and Nexa prefilled syringes, which addresses the need to streamline device approval by establishing comprehensive compatibility testing, collaboration between suppliers and validated solutions for drug delivery
Support from healthcare teams counts, as obesity will likely require long-term care, not just quick fixes